The burgeoning popularity of tirzepatide , initially for blood sugar control , is creating significant buzz within the UK , prompting a notable shift in hormone trends. Availability these treatments remains a complex situation , with NHS provision currently limited and specialist practices offering therapy at a premium . Concerns are being raised r